BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2024

May 15, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2024-05-13

Reporting Person: Barnes Alane P (Chief Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-13	Common Stock	P	5000	$5.53	Acquired	300762	Direct

Footnotes

F1: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $5.36 to $5.64. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.